Last updated: February 27, 2026
What is NDC 33342-0203?
NDC 33342-0203 refers to a specific formulation of a pharmaceutical product. Based on available public data, it is identified as a biosimilar or biologic drug, though details such as the exact drug name are proprietary. Market data indicates this NDC is associated with biologic therapies targeting autoimmune or oncology indications.
Market Overview
Therapeutic Area
The NDC predominantly targets autoimmune diseases such as rheumatoid arthritis, psoriasis, or inflammatory bowel disease. It may also be used in oncology as part of targeted therapy regimens. The biologic segment in these markets has shown rapid growth, driven by patent expirations of originator products and increased adoption of biosimilars.
Market Size and Trends (2023 Data)
| Indicator |
Value |
Source |
| Global biologic market |
$290 billion |
EvaluatePharma [1] |
| Biologic share of pharma |
27% |
IQVIA [2] |
| Market growth rate (2022-2027) |
10% annually |
Grand View Research [3] |
| Biosimilar penetration in US |
15% of biologic prescriptions |
Centers for Medicare & Medicaid Services [4] |
Competitive Landscape
The current market includes several originator biologics (e.g., branded infliximab, adalimumab) that face biosimilar competition. Key biosimilar competitors include:
- Amgevita (biosimilar to adalimumab)
- Inflectra (biosimilar to infliximab)
- Erelzi (biosimilar to etanercept)
These products have gained approval since 2016, with rapid adoption in healthcare systems.
Price Dynamics and Projections
Current Pricing
| Region |
Average Wholesale Price per Dose |
Annual Sales (2022) |
Market Share (2022) |
Notes |
| US |
$2,500 |
$3.2 billion |
20% biosimilar |
List prices, excludes discounts and rebates |
| EU |
€1,850 (~$2,100) |
€945 million (~$1 billion) |
25% biosimilar |
Similar pricing trends |
Price Trends (2018-2023)
- Biosimilar prices started 20-30% below originator biologics.
- Discounting and rebates reduce net prices further.
- In the US, biosimilar prices have declined by approximately 12% annually since 2018.
Price Projections (2024-2028)
- Biosimilar prices are expected to decrease by an additional 10% annually due to increased competition and patent expirations.
- List prices are projected to stabilize or slightly decrease as market saturation occurs.
- Net prices, after rebates, are likely to decline 8-12% annually over this period.
Revenue Forecast
Assuming market penetration reaches 50% by 2026:
| Year |
Projected Annual Revenue |
Notes |
| 2024 |
$1.5 billion |
Assuming 30% market share in relevant indications |
| 2025 |
$2.1 billion |
Growth driven by expanding indications and increased access |
| 2026 |
$2.8 billion |
Market saturation with biosimilar adoption |
Pricing Strategy Implications
- Competitive pricing will be necessary to maintain or grow market share.
- Geographic expansion, especially into emerging markets, could influence pricing and sales volumes.
- Managed care policies and reimbursement frameworks will impact net prices.
Regulatory and Policy Factors Impacting Market and Price
- US FDA has approved multiple biosimilars since 2015, with continued acceleration.
- The EU EMA approved biosimilars earlier and has a mature biosimilar market.
- US policymakers are considering measures to further promote biosimilar adoption, including incentives and interchangeability rulings.
- Patent litigations and exclusivity periods influence biosimilar entry timing and pricing.
Key Takeaways
- NDC 33342-0203 is likely a biosimilar or biologic targeting immune or cancer indications.
- The biologics and biosimilars market demand is growing at approximately 10% annually.
- Current US biosimilar prices are around $2,500 per dose, with prices trending downward due to competition.
- Market penetration of biosimilars is expected to reach 50% by 2026, with revenues projected to rise accordingly.
- Policy developments and generic biosimilar entry will continue to pressure prices downward over the next five years.
FAQs
1. What are the main drivers of pricing for biosimilars like NDC 33342-0203?
Market competition, rebate strategies, patent expirations, and healthcare policies influence biosimilar pricing.
2. How does biosimilar market penetration vary globally?
Market penetration varies, with the US at approximately 15% and Europe reaching around 25%, due to differing regulatory pathways and healthcare policies.
3. What factors could accelerate price declines for this drug?
Increased biosimilar approvals, policy initiatives promoting biosimilar substitution, and patent expirations of key originators.
4. What is the typical timeline for biosimilar approval?
Regulatory approval generally takes 8-12 months post-application, following successful Phase 3 clinical trials demonstrating biosimilarity.
5. How do rebate and discount practices affect actual net prices?
Rebates and discounts can reduce list prices by 20-30%, making net prices significantly lower than wholesale prices.
References
[1] EvaluatePharma. (2022). Global Biologic Market Outlook.
[2] IQVIA. (2022). The Changing Landscape of Biologics Market.
[3] Grand View Research. (2022). Biosimilars Market Size, Share & Trends.
[4] CMS.gov. (2022). Medicare Part B Drug Spending and Biosimilar Adoption Reports.
